TNFSF10 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 14 bp deletion in exon 1.
A549
Human
Lung
Liquid
Sanger Sequencing
Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 14 bp deletion in exon 1
Apo-2 ligand, Apo-2L, CD253, CD253 antigen, Chemokine tumor necrosis factor ligand superfamily member 10, Protein TRAIL, TNF related apoptosis inducing ligand TRAIL, TNF-related apoptosis-inducing ligand, TNF10_HUMAN, TNFSF10, TRAIL, Tumor Necrosis Factor (ligand) Superfamily Member 10, Tumor necrosis factor (ligand) family member 10, Tumor necrosis factor apoptosis inducing ligand splice variant delta, Tumor necrosis factor ligand superfamily member 10
TNFSF10 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 14 bp deletion in exon 1.
A549
Human
Lung
Liquid
Sanger Sequencing
Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 1 and 14 bp deletion in exon 1
Puromycin 1µg/mL
Carcinoma
TNFSF10
Knockout
CRISPR technology
Sanger Sequencing
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
EU: 1 US: 1
Adherent
Male
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
F-12K + 10% FBS
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Dry Ice
-196°C
-196°C
Recommended control: Human wild-type A549 cell line (Human wild-type A549 cell line ab255450). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
This supplementary information is collated from multiple sources and compiled automatically.
TRAIL also known as TNF-related apoptosis-inducing ligand plays an important role in inducing apoptosis. This protein has a mass of around 32 kDa and is expressed across various tissues including immune cells. TRAIL interacts with specific receptors on the cell surface to initiate a signaling cascade that results in programmed cell death. It is an attractive therapeutic target because of its selective ability to induce apoptosis in cancer cells while sparing most normal cells.
TRAIL's function extends beyond inducing cell death. It is an important member of the tumor necrosis factor (TNF) superfamily which regulates immune responses and inflammation. TRAIL can form a homotrimeric complex allowing it to bind effectively to death receptors on target cells specifically DR4 and DR5 triggering a series of downstream signaling events. This interaction is significant in modulating immune surveillance and tumor suppression.
TRAIL is integral to both intrinsic and extrinsic apoptosis pathways. Through these pathways TRAIL is closely related to FADD and caspase-8 which are important for apoptosis induction. The extrinsic pathway involves binding to TRAIL death receptors leading to DISC formation while the intrinsic pathway involves mitochondrial events mediated by members of the Bcl-2 protein family.
TRAIL has a significant connection with cancer and autoimmune diseases. TRAIL plays a dual role in cancer where it acts as a tumor suppressor but can also promote tumor progression if cancer cells become resistant to its effects. In cancer TRAIL’s interaction with proteins like FLIP can alter the apoptotic potential of the cells. In autoimmune diseases TRAIL's dysregulation can contribute to tissue damage due to increased immune activity highlighting its complex role in maintaining immune balance.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Representative images of TNFSF10 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using an EVOS M5000 microscope.
Allele-2: 11 bp deletion in exon 1.
Allele-1: 14 bp deletion in exon1
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com